COVID-19 positive outpatients are at an increased risk of neurodegenerative disorders compared with individuals who tested negative for the virus, a new study presented today at the 8th European Academy of Neurology (EAN) ...
Jun 24, 2022
0
2249
(Medical Xpress)—What do rheumatoid arthritis, type I diabetes, myasthenia gravis, multiple sclerosis, rheumatic heart disease, and narcolepsy have in common? All of these (and many other) apparently unrelated disorders ...
Argenx, a Belgian drug maker, recently announced a successful phase 3 ADAPT trial of its experimental drug, efgartigimod. The company plans to seek U.S. approval of the drug by the end of year as a potential new treatment ...
May 29, 2020
0
12
Evidence from a small-scale clinical trial suggests that a variation of the advanced blood cancer immunotherapy known as CAR-T could be adapted to treat myasthenia gravis, an autoimmune disorder of the nervous system. The ...
Jun 22, 2023
0
51
Autoimmune disorders may share certain pathogenic mechanisms with cancer, according to a new report by George Washington University (GW) researcher Linda Kusner, Ph.D., published in PLOS ONE on July 22.
Jul 22, 2014
0
0
There are many forms of autoimmune disease, but by definition they all have one thing in common—they arise when the body's immunological defenses go awry and attack our cells or trigger biochemical changes that lead to ...
Jan 25, 2023
0
11
In a global study of myasthenia gravis, an autoimmune disease that causes muscle weakness and fatigue, researchers found that surgical removal of an organ called the thymus reduced patients' weakness, and their need for immunosuppressive ...
Aug 10, 2016
0
42
Norwegian researchers have mapped genetic variations associated with an increased risk of multiple sclerosis (MS) and myasthenia gravis (MG), bringing science one step closer to understanding these serious autoimmune disorders.
Jan 9, 2014
0
1
(HealthDay)—Vyvgart (efgartigimod), a neonatal Fc receptor blocker (FcRn), was approved to treat generalized myasthenia gravis in adults who test positive for the anti-acetylcholine receptor (AChR) antibody, the U.S. Food ...
Dec 21, 2021
0
6
An antibody to a protein critical to enabling the brain to talk to muscles has been identified as a cause of myasthenia gravis, researchers report.
Nov 11, 2013
0
3
Myasthenia gravis (from Greek μύς "muscle", ἀσθένεια "weakness", and Latin: gravis "serious"; abbreviated MG) is an autoimmune neuromuscular disease leading to fluctuating muscle weakness and fatiguability. It is an autoimmune disorder, in which weakness is caused by circulating antibodies that block acetylcholine receptors at the postsynaptic neuromuscular junction, inhibiting the excitatory effects of the neurotransmitter acetylcholine on nicotinic receptors throughout neuromuscular junctions. Myasthenia is treated medically with cholinesterase inhibitors or immunosuppressants, and, in selected cases, thymectomy. The disease incidence is 3–30 cases per million per year and rising as a result of increased awareness. MG must be distinguished from congenital myasthenic syndromes that can present similar symptoms but offer no response to immunosuppressive treatments.
This text uses material from Wikipedia licensed under CC BY-SA
